Loading...

eFFECTOR Therapeutics, Inc.

EFTRW•NASDAQ
Healthcare
Biotechnology
$0.001
$-0.00(-80.00%)

eFFECTOR Therapeutics, Inc. (EFTRW) Stock Overview

Explore eFFECTOR Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.1/100

Key Financials

Market Cap1.4K
P/E Ratio-0.00
EPS (TTM)$-0.91
ROE7.23%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.00

EFTRW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of eFFECTOR Therapeutics, Inc. (EFTRW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.00 and a market capitalization of 1.4K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for EFTRWStats details for EFTRW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for EFTRWAnalyst Recommendations details for EFTRW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

CEO

Craig R. Jalbert CIRA

Employees

14

Headquarters

142 North Cedros Avenue, Solana Beach, DE

Founded

1970

Frequently Asked Questions

;